Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma
Authors
Keywords
TKIs, Crosstalk, mRCC, VEGFR, HIFs, RTKs, Targeted therapy
Journal
Cancer Cell International
Volume 18, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-03-05
DOI
10.1186/s12935-018-0530-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Updated European Association of Urology Guidelines: Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer
- (2018) Thomas Powles et al. EUROPEAN UROLOGY
- Recommendations for the Management of Rare Kidney Cancers
- (2017) Rachel H. Giles et al. EUROPEAN UROLOGY
- Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma
- (2017) James J. Hsieh et al. EUROPEAN UROLOGY
- Clinical development of mTor inhibitors for renal cancer
- (2017) Michele Ghidini et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
- (2017) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study
- (2017) Hans J. Hammers et al. JOURNAL OF CLINICAL ONCOLOGY
- Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas
- (2017) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma
- (2017) Nizar M. Tannir et al. Current Oncology Reports
- Effects of VEGF and VEGFR polymorphisms on the outcome of patients with metastatic renal cell carcinoma treated with sunitinib: a systematic review and meta-analysis
- (2017) Chenkui Miao et al. Oncotarget
- Overriding TKI resistance of renal cell carcinoma by combination therapy with IL-6 receptor blockade
- (2017) Kei Ishibashi et al. Oncotarget
- Renal cell carcinoma
- (2017) James J. Hsieh et al. Nature Reviews Disease Primers
- Effects of different ligands on epidermal growth factor receptor (EGFR) nuclear translocation
- (2016) Jerusa A.Q.A. Faria et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Insulin-like growth factor-1 signaling in renal cell carcinoma
- (2016) Adam F. Tracz et al. BMC CANCER
- Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma
- (2016) Martin H Voss et al. BRITISH JOURNAL OF CANCER
- Perivascular PDGFR-β is an independent marker for prognosis in renal cell carcinoma
- (2016) Magnus Frödin et al. BRITISH JOURNAL OF CANCER
- Exosome-Transmitted lncARSR Promotes Sunitinib Resistance in Renal Cancer by Acting as a Competing Endogenous RNA
- (2016) Le Qu et al. CANCER CELL
- A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma
- (2016) Eli M. Wallace et al. CANCER RESEARCH
- Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma
- (2016) Kathleen M. Mahoney et al. Clinical Genitourinary Cancer
- Cardiovascular Toxicities of Small Molecule Tyrosine Kinase Inhibitors: An Opportunity for Systems-Based Approaches
- (2016) S-A Brown et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Cabozantinib: A Review in Advanced Renal Cell Carcinoma
- (2016) Zaina T. Al-Salama et al. DRUGS
- Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer
- (2016) Johannes Schödel et al. EUROPEAN UROLOGY
- Cabozantinib for the treatment of renal cell carcinoma
- (2016) Bernard Escudier et al. EXPERT OPINION ON PHARMACOTHERAPY
- Tyrosine receptor kinase B silencing inhibits anoikis-resistance and improves anticancer efficiency of sorafenib in human renal cancer cells
- (2016) PENG ZHANG et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin
- (2016) Jianing Xu et al. JOURNAL OF CLINICAL INVESTIGATION
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
- (2016) Toni K Choueiri et al. LANCET ONCOLOGY
- Targeting renal cell carcinoma with a HIF-2 antagonist
- (2016) Wenfang Chen et al. NATURE
- Long noncoding RNA-SRLR elicits intrinsic sorafenib resistance via evoking IL-6/STAT3 axis in renal cell carcinoma
- (2016) Z Xu et al. ONCOGENE
- TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells
- (2016) D-W Wu et al. Cell Death & Disease
- Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
- (2016) Jeffrey J. Wallin et al. Nature Communications
- Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis
- (2016) Xinan Sheng et al. Oncotarget
- Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status
- (2015) Su-Jin Shin et al. ANNALS OF SURGICAL ONCOLOGY
- Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis
- (2015) J. E. Maxson et al. CANCER RESEARCH
- Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer
- (2015) L. Zhang et al. CLINICAL CANCER RESEARCH
- Insulin and IGFs in renal cancer risk and progression
- (2015) W Solarek et al. ENDOCRINE-RELATED CANCER
- Understanding Pathologic Variants of Renal Cell Carcinoma: Distilling Therapeutic Opportunities from Biologic Complexity
- (2015) Brian Shuch et al. EUROPEAN UROLOGY
- Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
- (2015) Robert J Motzer et al. LANCET ONCOLOGY
- A bi-functional antibody-receptor domain fusion protein simultaneously targeting IGF-IR and VEGF for degradation
- (2015) Yang Shen et al. mAbs
- Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation
- (2015) Tea Pemovska et al. NATURE
- Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor
- (2015) Y. Zhao et al. ONCOLOGIST
- FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor
- (2015) Koichi Azuma et al. Oncotarget
- ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
- (2014) Carlos L. Arteaga et al. CANCER CELL
- Exosome Transfer from Stromal to Breast Cancer Cells Regulates Therapy Resistance Pathways
- (2014) Mirjam C. Boelens et al. CELL
- Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy
- (2014) M. H. Voss et al. CLINICAL CANCER RESEARCH
- MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of pRCC with CGH Array and Matching Gene Expression Array
- (2014) L. Albiges et al. CLINICAL CANCER RESEARCH
- Carbonic Anhydrase 9 Expression Increases with Vascular Endothelial Growth Factor–Targeted Therapy and Is Predictive of Outcome in Metastatic Clear Cell Renal Cancer
- (2014) Grant D. Stewart et al. EUROPEAN UROLOGY
- Combination Strategy Targeting VEGF and HGF/c-met in Human Renal Cell Carcinoma Models
- (2014) E. Ciamporcero et al. MOLECULAR CANCER THERAPEUTICS
- The Met receptor tyrosine kinase: A key player in oncogenesis and drug resistance
- (2014) Christiane R. Maroun et al. PHARMACOLOGY & THERAPEUTICS
- Identification of Tissue microRNAs Predictive of Sunitinib Activity in Patients with Metastatic Renal Cell Carcinoma
- (2014) Celia Prior et al. PLoS One
- Targeting both IGF-1R and mTOR synergistically inhibits growth of renal cell carcinoma in vitro
- (2013) Thomas M Cardillo et al. BMC CANCER
- Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis
- (2013) V Damiano et al. BRITISH JOURNAL OF CANCER
- Buccodental side effects of sunitinib in patients with metastatic renal cell carcinoma
- (2013) M Gilabert et al. BRITISH JOURNAL OF CANCER
- A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma
- (2013) Tomohiro Funakoshi et al. CANCER TREATMENT REVIEWS
- The Effect of VEGF-Targeted Therapy on Biomarker Expression in Sequential Tissue from Patients with Metastatic Clear Cell Renal Cancer
- (2013) K. Sharpe et al. CLINICAL CANCER RESEARCH
- Vascular endothelial-cadherin stimulates syndecan-1-coupled insulin-like growth factor-1 receptor and cross-talk between αVβ3 integrin and vascular endothelial growth factor receptor 2 at the onset of endothelial cell dissemination during angiogenesis
- (2013) Alan C. Rapraeger et al. FEBS Journal
- Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: New strategies for overcoming resistance to VEGFR and mTORC1 inhibitors
- (2013) Robert A. Figlin et al. INTERNATIONAL JOURNAL OF CANCER
- The ErbB/HER family of protein-tyrosine kinases and cancer
- (2013) Robert Roskoski PHARMACOLOGICAL RESEARCH
- IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations
- (2013) Alejandro Vazquez-Martin et al. Scientific Reports
- VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer
- (2012) M. Terme et al. CANCER RESEARCH
- EGFR expression is linked to osteopontin and Nf-κB signaling in clear cell renal cell carcinoma
- (2012) K. Matušan-Ilijaš et al. Clinical & Translational Oncology
- Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials
- (2012) Hai T Tran et al. LANCET ONCOLOGY
- The VHL/HIF axis in clear cell renal carcinoma
- (2012) Chuan Shen et al. SEMINARS IN CANCER BIOLOGY
- Metformin Accelerates the Growth of BRAF V600E -Driven Melanoma by Upregulating VEGF-A
- (2012) Matthew J. Martin et al. Cancer Discovery
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
- (2011) Samuel A. Wells et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- Tyrosine kinase expression profile in clear cell renal cell carcinoma
- (2011) Turang E. Behbahani et al. WORLD JOURNAL OF UROLOGY
- Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma
- (2010) D. Huang et al. CANCER RESEARCH
- Effects of combined valproic acid and the epidermal growth factor/vascular endothelial growth factor receptor tyrosine kinase inhibitor AEE788 on renal cell carcinoma cell linesin vitro
- (2009) Eva Juengel et al. BJU INTERNATIONAL
- Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer
- (2009) Tetsuya Mitsudomi et al. FEBS Journal
- Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
- (2008) D. D. Hu-Lowe et al. CLINICAL CANCER RESEARCH
- Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma
- (2008) Manuela Schmidinger et al. JOURNAL OF CLINICAL ONCOLOGY
- R Regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways
- (2008) Yihai Cao et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Signaling networks assembled by oncogenic EGFR and c-Met
- (2008) A. Guo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search